

CT:VQ™ enters US Outpatient Market via SimonMed's 170-site network

29 May 2026

Highlights

- 4DMedical secures commercial contract for CT:VQ™ with SimonMed Imaging, operator of more than 170 outpatient imaging centers across the U.S.
- Agreement delivers immediate clinical deployment of CT:VQ™ and LDA^f™ on commercial terms from day one, reflecting growing confidence in the technology
- SimonMed is one of the largest, fastest growing and most influential outpatient imaging providers in the United States, operating across 10 states
- Through partnership, SimonMed will support the development of reimbursement evidence for CT:VQ™ across public and private payors
- Strengthens 4DMedical's position as a partner of choice for next-generation CT-based functional imaging in the U.S.

Melbourne, Australia, 29 May 2026: 4DMedical Limited (ASX: 4DX, "4DMedical" or the "Company"), a global leader in respiratory imaging technology, today announces that it has entered into a commercial agreement with SimonMed Imaging (SimonMed), one of the leading outpatient medical imaging providers in the United States.

Extending CT:VQ™ into one of the largest outpatient imaging networks in the U.S.

SimonMed, headquartered in Scottsdale, Arizona, is one of the most influential, physician-led radiology groups in the United States. Founded in 2003, it operates over 170 imaging centers across 10 states, supported by a team of over 300 radiologists, and has built its national network around high-access, community-based imaging. SimonMed is recognised for its methodical approach to technology adoption, thoroughly validating new capabilities before deploying them at scale. This disciplined approach safeguards quality of care while maximising clinical impact across one of the largest outpatient imaging networks in the US.

Quantitative cardiopulmonary analysis to support radiologist review

Under the three-year agreement, SimonMed will deploy 4DMedical's advanced quantitative cardiopulmonary analysis solutions, CT:VQ™ and LDA^f™, to complement its existing CT imaging services, supporting enhanced clinical decision-making for pulmonary assessment. The agreement leverages 4DMedical's scalable SaaS delivery model, supporting efficient deployment across large multi-site networks.

While the agreement is not immediately financially material, the deployment with SimonMed represents a clear commercial win for 4DMedical, and a material long-term opportunity. Key terms include:

- Immediate clinical deployment on commercial terms from day one, reflecting growing confidence in the technology;
- Three-year agreement, with pricing based on 4DMedical's per-scan rates; and
- Partnership with SimonMed, supporting the development of reimbursement evidence and sharing insurance and claims data across its network, informing payor engagement for CT:VQ™.



The collaboration reflects a shared commitment to advancing precision diagnostics in lung health. By integrating 4DMedical's quantitative functional lung analysis with conventional CT imaging, SimonMed aims to provide referring clinicians with deeper, objective insights into regional lung function, supporting more informed diagnosis, treatment planning, and patient management, whilst leveraging reimbursement opportunities across their network.

Dr. Sean Raj, MD, MBA, Chief Medical Officer and Chief Innovation Officer, SimonMed, said:

"Innovation has always been central to SimonMed's mission of bringing advanced imaging technologies to communities across the country. 4DMedical's technology is an exciting example of how we can transform routine imaging into a far more quantitative and clinically actionable tool. By extracting functional cardiopulmonary information directly from standard CT scans without additional contrast or nuclear medicine studies, we believe this technology has the potential to help physicians identify diseases that affect millions of patients, including asthma and COPD, earlier, stratify risk more precisely, and ultimately support more personalized care and better outcomes for patients."

4DMedical MD/CEO and Founder Andreas Fouras said:

SimonMed is one of the largest and most influential outpatient imaging providers in the United States. Their decision to adopt CT:VQ™, moving directly to commercial deployment, is a major milestone for 4DMedical and a strong validation of both our technology and our clinical value.

In just months since FDA clearance, we have established CT:VQ™ across leading Academic Medical Centers and are now extending into large-scale imaging networks. This agreement demonstrates that adoption by world-class clinical innovators is translating directly into commercial uptake across high-volume providers.

The commercial structure of this agreement is particularly compelling. With no evaluation phase and immediate deployment on commercial terms, it reflects growing confidence in the clinical and operational value of CT:VQ™.

By enabling comprehensive cardiopulmonary analysis from a standard CT scan, including lung function assessment and cardiac risk insights, CT:VQ™ allows providers like SimonMed to extract significantly greater value from existing imaging workflows.

We have unstoppable momentum in the U.S., and this partnership only strengthens that trajectory. It will drive revenue growth while reinforcing our confidence in reimbursement for CT:VQ™.

We have established a position of strength across leading academic medical centers, and with this addition of a large, fast-growing and influential radiology network, we are now extending that leadership into scaled commercial deployment. With increasing reimbursement visibility and expanding market adoption, we expect this momentum to accelerate further.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Investor Relations

investor.relations@4dmedical.com

Administration

Company Secretary

companysecretary@4dmedical.com

Media Enquiries

Julia Maguire

julia@thecapitalnetwork.com.au



About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionizing respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology**[®] transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS[®])**, **CT LVAS[™]**, and the ground-breaking **CT:VQ[™]** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalized patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com

For personal use only